• Ann Tucker

FDA issues warning letter to e-cigarette manufacturer

The Food and Drug Administration (FDA) recently issued a warning letter to an e-liquid manufacturer for violations of the Federal Food, Drug, and Cosmetic (FD&C) Act, including marketing new tobacco products without authorization; marketing tobacco products with false and misleading advertising; and marketing unauthorized modified risk tobacco products. The FDA also noted in their letter that StemStix, the manufacturer receiving the warning, made false and misleading statements on its website that referenced FDA testing and marketed their e-liquid products as modified risk tobacco products without the required FDA order in effect. Finally, the warning letter also notes that StemStix violated the FD&C Act by marketing new tobacco products without authorization. As described in the letter, the products were introduced or modified after August 8, 2016 – the effective date of the final rule that extended the FDA’s authority to all tobacco products. The letter requests that StemStix provide a written response within 15 working days describing corrective actions and a plan for maintaining compliance with the FD&C Act.

1 view0 comments

Recent Posts

See All

SAMHSA (11/10) –– The Substance Abuse and Mental Health Services Administration is pleased to announce the release of the agency’s Interim Strategic Plan (ISP), which presents a new mission and vision

The White House budget office is reviewing a draft SAMHSA rule that would make permanent the COVID-19 methadone take-home waiver and define which patients with OUD are considered “stable” enough to re